Dupilumab for the treatment of pembrolizumab-induced bullous pemphigoid: A case report

Dermatol Ther. 2022 Aug;35(8):e15623. doi: 10.1111/dth.15623. Epub 2022 Jun 24.
No abstract available

Keywords: bullous drug eruption; bullous pemphigoid; dupilumab; immune-related adverse events; immunotherapy; pembrolizumab.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects
  • Humans
  • Pemphigoid, Bullous* / chemically induced
  • Pemphigoid, Bullous* / diagnosis
  • Pemphigoid, Bullous* / drug therapy

Substances

  • Antibodies, Monoclonal, Humanized
  • dupilumab
  • pembrolizumab